Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;205(4):1267-1268.
doi: 10.1111/bjh.19777.

What is the best second-line treatment for immune thrombocytopenia?

Matthieu Mahévas  1 , James B Bussel  2
Affiliations

What is the best second-line treatment for immune thrombocytopenia?

Matthieu Mahévas et al. Br J Haematol. 2024 Oct.

Abstract

The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain weaknesses. Stolz et al. describe a single-centre experience that whets our appetite for a large randomized controlled trial comparing a TPO agonist and an anti-CD20 agent. Commentary on: Stolz et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia - A single center retrospective analysis. Br J Haematol 2024; 205:1121-1125.

Keywords: ITP; TPO agents; anti‐CD20 agent.

PubMed Disclaimer

References

REFERENCES

    1. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.
    1. Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123.
    1. Khellaf M, Charles‐Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–3236.
    1. Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham‐Rundles S, Godeau B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995.
    1. Deshayes S, Khellaf M, Zarour A, Layese R, Fain O, Terriou L, et al. Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP‐ritux. Am J Hematol. 2019;94(12):1314–1324.

MeSH terms

LinkOut - more resources